{"entity":{"id":"nct06714357","kind":"trial","name":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","aka":["VICTORIA"],"tldr":"A phase 2 trial of fOLFIRI (5-FU, leucovorin, irinotecan) and panitumumab in colorectal cancer, run by National Cancer Institute, Naples, now recruiting.","summary":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06714357 by National Cancer Institute, Naples, with a registry enrolment figure of 130 participants, started 2025-03-12 and due to reach its primary completion in 2026-12-20. Interventions recorded: irinotecan; panitumumab; Valproic Acid (VPA). Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Study Part 1 - Progression Free Survival rate at 16 weeks in the two arms.. Colorectal eligibility wording from the registry: \"Histologically proven of colorectal adenocarcinoma\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06714357","url":"https://clinicaltrials.gov/study/NCT06714357"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["folfiri","panitumumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06714357","phase":"2","setting":"Randomized Phase 2 Study of Valproic Acid Combined With Rechallenge Anti-EGFR Based Regimen Regimens in Pretreated Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer - VICTORIA Trial","sponsor":"National Cancer Institute, Naples","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06714357/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}